- Home
- IRT vs SWTX Comparison
IRT vs SWTX Comparison
Compare IRT & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- SWTX
- Stock Information
- Founded
- IRT 2009
- SWTX 2017
- Country
- IRT United States
- SWTX United States
- Employees
- IRT N/A
- SWTX N/A
- Industry
- IRT Real Estate Investment Trusts
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- SWTX Health Care
- Exchange
- IRT Nasdaq
- SWTX Nasdaq
- Market Cap
- IRT 4.3B
- SWTX 3.5B
- IPO Year
- IRT 2013
- SWTX 2019
- Fundamental
- Price
- IRT $17.73
- SWTX $46.96
- Analyst Decision
- IRT Buy
- SWTX Buy
- Analyst Count
- IRT 10
- SWTX 7
- Target Price
- IRT $22.70
- SWTX $56.86
- AVG Volume (30 Days)
- IRT 1.9M
- SWTX 4.9M
- Earning Date
- IRT 07-30-2025
- SWTX 08-06-2025
- Dividend Yield
- IRT 3.84%
- SWTX N/A
- EPS Growth
- IRT N/A
- SWTX N/A
- EPS
- IRT 0.13
- SWTX N/A
- Revenue
- IRT $641,330,000.00
- SWTX $219,670,000.00
- Revenue This Year
- IRT $5.23
- SWTX $74.36
- Revenue Next Year
- IRT $6.20
- SWTX $75.63
- P/E Ratio
- IRT $136.48
- SWTX N/A
- Revenue Growth
- IRT N/A
- SWTX 730.42
- 52 Week Low
- IRT $17.10
- SWTX $28.21
- 52 Week High
- IRT $22.26
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- IRT 35.61
- SWTX 63.41
- Support Level
- IRT $17.74
- SWTX $46.74
- Resistance Level
- IRT $18.02
- SWTX $46.92
- Average True Range (ATR)
- IRT 0.37
- SWTX 0.11
- MACD
- IRT -0.04
- SWTX -0.08
- Stochastic Oscillator
- IRT 10.22
- SWTX 84.81
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.